What about K-drug sales of more than $10 billion PD-(L)1 drug sales in 2019?

To date, a total of 10 PD-(L)1 cancer immunotherapy drugs have been available worldwide, including four domestic and six multinational pharmaceutical companies: BMS's Opdivo, Mercado's Keytruda, AZ's Imfinzi, Roche's Tecentriq, Pfizer and Merck's partnership with Sanofi and Research and DevelopmentAmong them, Infinfan, Tai Sanqi and Bavencio for PD-L1 drugs, O'Devo, Corida, Infiniti and Tai Sanqi have been approved in the domestic marketDomestic PD-(L)1 approved to list has been more than a year, E drug managers have counted four domestic PD-(L) 1: Cinda, Junshi, Hengrui and Baiji Shenzhou listed sales in the first year, domestic PD-(L)1 listed since the multinational pharmaceutical companies PD-(L)1 global sales?(2019 six PD-1 1 drug sales and year-on-year growth, data source: companies 2019 results)01 BMS-Opdivo (Navuliyu monoantigen)sales: $8.015 billionYear-over-year growth: about 7%BMS Opdivo is the world's first pD-1 drug listed in Japan in July 2014BMS's 2019 results show opdivo sales were $8,015 million, up about 7% from the same period in 2018BmS's total revenue in 2019 was $26.15 billion, the 10th largest among global multinational pharmaceutical companies, with Opdivo's sales accounting for nearly 30% of its annual revenueIn 2018, Opdivo is the world's top-ranked PD-1 drug with sales of $6.735 billionOpdivo is also the first PD-1 drug to be approved for market ingressment in China, and was approved by the FDA in October 2018, breaking the gap in domestic treatment drugs in this areaListed approved for indication sittatives are in adult patients with late localized or metastatic non-small cell lungsIndustry insiders have predicted that Opdivo's first year of sales in China will exceed Rmb1bnin addition, it is worth noting that Opdivo's revenue in the first quarter of 2020 was just $1.766 billion, down 1.9 percent from a year earlier, less than one-fifth of BMS' total revenue in the first quarter of 2020But BMS's first-quarter revenue, which accounted for 71% of growth, had a big impact on the acquisition of new-base in the previous yearOverall, however, its quarterly report also showed that "the increased demand for COVID-19-related drugs caused by the new corona outbreak, as well as patient hoarding, contributed to an 8% increase in Q1 drug sales." Giovanni Caforio, chief executive ofBMS, has said that "the merger will create the world's 'first' oncology product line in the field of solid and blood tumors." The combined development pipeline pillar will build on the "heavy-duty drugs" checkpoint inhibitors Opdivo, Yervoy and the best-selling myeloma treatment drugs Revlimid and PomalystIn March, Opdivo and Yervoy Immune Portfolio programs for the treatment of patients with advanced hepatocellular carcinoma received FDA approval, the only FDA-approved dual immunotherapy that has acquired four types of cancer, melanoma, renal cell carcinoma, colorectal cancer, and hepatocellular carcinomafrom the indications of indications, so far Opdivo has been approved abroad for melanoma, non-small cell lung cancer, small cell lung cancer, advanced renal cell carcinoma, classic Hodgkin lymphoma and other 10 types of cancer, of which 3 indications were approved in ChinaIn fact, the domestic PD-(L)1 drug, Hengrui's Carrey Pearl single anti-market nearly a year approved 2 indications has been the fastest domestic manufacturersfrom the price point of view, public information shows that Opdivo in China's price of 9062 yuan / 100 mgFor low-income patients, the drug program is 3-3, 3-4, that is, the patient first self-funded use of 3 courses, you can get 3 courses of medicine, and then self-funded use of 3 courses of medicine, can get 4 courses of medicineThe follow-up is repeated until the disease progresses or is treated for 2 years02 Mersadon-KeytrudaSales: $11.1 billionYear-over-Year: 55%Mersadon's Keytruda is the world's second approved PD-1 drug, which was approved in the U.Sin September 2014, with first-year sales of $566 million2019 is a breakthrough year for PD-(L)1 drugs, with domestic drugs coming on sale, and Keytruda sales surpassing Opdivo for the first time in 2018, breaking the $10 billion mark for the first time in 2019, reaching $11.1 billion in sales and joining top-3 global drug sales in 2019total revenue for the year 2019 was $46.84 billion, up 11% year-on-year, with Keytruda's sales contributing more than a fifth of its revenue, up 55 percent from 2019Under the impact of the outbreak, Keytruda sales remained strong in the first quarter of 2020, with total sales of $3.284 billion, up 45%, and Total revenue in the first quarter of Mersaeast was $12.57 billion, up 11% YoYcomes after GlobalData, the world's leading data analytics firm, reported that Kaytruda would surpass Sumey to pped the $22.5 billion list and move ahead of second-place Eliquis In addition, The top 10 drugs that EvaluatePharma releases for 2020 sales growth also show that Keytruda will generate revenue of $14.39 billion in 2020 , of course, Keytruda's impressive sales are due to its clinical breakthrough, and since 2014, Keytruda has been approved for more than 22 indications, including melanoma, non-small cell lung cancer, small cell lung cancer, head and neck cancer and more than 14 other types of cancer At present, advanced melanoma, combined penicillin and platinum chemotherapy drugs first-line treatment of EGFR mutation negative and ALK negative metastatic non-squamous non-small cell lung cancer, as well as single-drug first-line treatment PD-(L)1 positive expression of advanced non-small cell lung cancer three indications have been approved in China It is worth noting that Keytruda is currently conducting 1,000 clinical trials, more than 75 registered clinical trials are under way, and more than 600 joint treatment programs are in the works, according to E Drug Manager K medicine in China for 17918 yuan / 100mg, although currently entered the national health insurance directory only Sindili monoantigen, but in 2020 Keytruda's drug program will be upgraded: 2 plus 2, 2 plus 3, that is, the first round of charity medicine, patients only need to use 2 courses of medicine at their own expense, you can get 2 courses of medicine Then, at a cost of 2 treatments, you can get a charity bonus of 3 courses Another 2 courses of medicine at their own expense, and 3 courses of medicine can be obtained Keep it circulating until the disease progresses, or you have been using K medicine for 2 years 03 Roche-Tecentriq Global Sales: Approximately $1.927 billion YoY: 3.9% Roche's Tecentriq is the world's first PD-L1 drug, tecentriq approved for listing in May 2016 Specific metastatic urinary skin cancer, sales in 2017 was CHF 487 million, compared with Year's annual revenue of 53.299 billion Swiss francs, of which the pharmaceutical business generated 41.22 billion Swiss francs, led by Ocrevus, Tecentriq, Perjeta and Alecensa Roche's 2019 results showed full-year revenue of 61.5 billion Swiss francs, up 8 percent from a year earlier, and pharmaceutical revenue of 48.5 billion Swiss francs, of which Tecentriq sales were SFr1.875 billion, up 143 percent year-on-year is worth noting that Tecentriq recently was approved by China's Drug Administration listed, announced pricing in March, 32800 yuan / 1200 mg, the drug program is 2 and 3, that is, after receiving 2 at his own expense at the end of the attiletamono treatment, after the designated doctor assessed that patients can benefit from attalizumab treatment or no progress in the disease, patients can receive up to 3 follow-up drug assistance Tecentriq has been approved for nearly 10 types of cancer, including lung, bladder, bowel and breast cancer, and it is worth noting that Tecentriq is currently the only cancer immunoinnovative drug in China for the first-line treatment of a wide range of small cell lung cancer 04 AZ-Imfinzi Global Sales: $1,469 million
YoY: 132% AZ's Imfinzi is the world's second PD-L1 drug, which was approved in the U.S in May 2017 with first-year sales of $633 million AstraZeneca's 2019 results show that Imfinzi's 2019 sales were $1,469 million, while AZ's full-year 2019 revenue was $24.384 billion, up 10 percent year-on-year, and it's worth noting that Imfinzi's sales grew 132.1 percent year-on-year Imfinzi also performed well in the first quarter of 2020, generating $462 million in revenue, up 57 percent from a year earlier In the first quarter, AZ's total revenue was $6.354 billion, up 16% YoY, and it is worth noting that AZ China revenue was $1.416 billion, up 14% YoY, accounting for 22.29% of global revenue, and in December 2019 Imfinzi was approved for listing in China in terms of adaptation certificate, so far Infifan has been approved non-small cell lung cancer, urinary skin cancer and small cell lung cancer, of which non-small cell lung cancer has been approved in the country, not long ago, The British Freefan United Trememumab for bladder cancer phase III clinical trial survival rate did not exceed the first-line standard therapy, which shows that Imfinzi temporarily no bladder cancer in terms of price, in early 2020 AZ announced the price of Imfinzi in China, 6066 yuan / 120mg, the drug program is 2 plus 2, 4 , 4 , 6 , 8, that is, the first round, patients use 2 courses of the duvaliu monoresist, can get free 2 courses of drug assistance after the treatment of 2 courses of drug assistance In the second round, patients can obtain free drug assistance for 4 courses of drug assistance after using 4 courses of dafreliu monoantigen at their own expense, and in the third round, patients can obtain free drug assistance of 8 courses of free medicine, and can be re-applied for free medicine spending on the premise that the disease does not progress 05 Merck and Pfizer-Bavencio Global Sales: Approximately US$111 million YoY: 48% Merck and Pfizer Jointly Developed Bavencio was approved by the FDA in March 2017, achieving sales of EUR 21 million in 2018, EUR 69 million in 2018 and Bavencio sales of EUR 103 million in 2019, up 48% YoY Bavencio sales are far from the four drugs mentioned above, in addition to late approval, less indications, and Bavencio clinical trials repeatedly failed, breakthroughs are less relevant According to statistics, in 2018 Bavencio in the three major cancers of ovarian cancer, stomach cancer, lung cancer three stage III clinical failure, in 2019 in the stomach cancer again failed 06 Sanofi and Regenerative-Libtayo Global Sales: $211 million
First Year of Listing Sanofi and Regenerative Yuan Jointly Developed Libtayo was approved by the FDA in September 2018, and the first indication applied for was metastatic/local advanced skin squamous cell carcinoma, with sales of $211 million in 2019 A month ago, Sanofi and Regeneration announced that a Phase III clinical trial of Libtayo for non-small cell carcinoma had reached its total survival and was terminated early PD-(L)1 drug from research and development to market is not a short road, requires a large-scale investment of enterprises, looking at O drugs, K drugs nearly 10 billion annual sales, as well as more than 20 indications, the first year sales of 1 billion yuan, the adaptable more single domestic PD-(L) 1 block and long.